From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with T1D, and GLP-1 RA prescriptions also increased.

Federal cuts to funding could “decimate” medical research in the US, delaying cures and costing countless lives.

There may be lower risk for HF among patients with low-to-moderate total alcohol consumption, except in women who drink beer, who may have higher risk.

Patients with infection-related hospitalization may have increased risk for incident heart failure, including HFrEF and HFpEF.

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

Dupilumab in atopic dermatitis treatment had the most favorable cardiometabolic safety profile when compared with methotrexate and cyclosporine.

Dapagliflozin reduced the risk of death or worsening heart failure in older patients with aortic stenosis who underwent transcatheter aortic-valve implantation.

Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with diabetes.

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

A 2-item food security instrument captures similar mortality risk information as instruments with more items among adults in the US.

Topline data were announced from a phase 3 trial evaluating setmelanotide for the treatment of acquired hypothalamic obesity.